Medical Oncology

Polycythemia Vera

Questions discussed in this category

Under which circumstances would you prefer ropeginterferon over hydroxyurea for patients with Polycythemia Vera?

Ropeginterferon is now a preferred therapy for Polycythemia Vera (PV) as per a recent update to the NCCN guidelines.

1 Answer available

Papers discussed in this category

Blood, 2010-04-08

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.

Blood, 2008-07-15

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.

Seminars in hematology, 1986-04

Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.

N Engl J Med, 2014 Aug 28

Two clinical phenotypes in polycythemia vera.

Leukemia, 2021 Apr 28

Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?

Blood, 2022 May 12

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.

Haematologica, 2019 Apr 04

Distinguishing essential thrombocythemia V617F from polycythemia vera: limitations of erythrocyte values.

Blood, 1997 Nov 01

Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.

Blood, 2023 Nov 30

Moving toward disease modification in polycythemia vera.

Blood, 2008 Jan 10

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.

Lancet (London, England), 1978 Dec 09

Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.

Related Topics in Medical Oncology